Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients.
The pharmacokinetics of clobazam were studied in six healthy volunteers and six age and sex matched enzyme-induced epileptic patients. In the epileptic patients the area under the plasma concentration-time curve for clobazam was significantly smaller and the area under the plasma concentration-time curve for N-desmethylclobazam was significantly greater than in the healthy volunteers. Plasma N-desmethylclobazam concentrations were found to be much higher than those of clobazam in the epileptic patients, raising the possibility that the antiepileptic properties of clobazam are to be attributed more to its metabolite than the parent drug.
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants / Q000378:metabolism*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000097:blood / Q000378:metabolism*; D002220:Carbamazepine / Q000097:blood; D000078306:Clobazam; D004790:Enzyme Induction / Q000187:drug effects; D004827:Epilepsy / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D010672:Phenytoin / Q000097:blood
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D001570:Benzodiazepinones; D001569:Benzodiazepines; D000078306:Clobazam; D002220:Carbamazepine; D010672:Phenytoin; C024581:N-desmethylclobazam